Skip to content

Study · Randomized controlled trial · n = 45 · 2021

6 results

Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.

Bailey TS, Willard J, Klaff LJ, Yager Stone J, Melgaard A, Tehranchi R

Diabetes, obesity & metabolism19 Jul 2021Cited by 12 (Europe PMC)

PMID34169625 (opens in a new tab)DOI10.1111/dom.14475 (opens in a new tab)PepBankPUB-34169625
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In type 1 diabetes, median recovery time was 10.0 (95% CI 8.0; 12.0) minutes with dasiglucagon versus 35.0 (20.0; -) with placebo (P < .001).

    In plain wordsDasiglucagon restored glucose faster than placebo.

    Peptide
    Dasiglucagon
    Outcome
    DecreaseTime to glucose recovery
    Study

    n = 45

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6 mg · subcutaneousAs given in this study (human).

    Measurements

    Median time to recovery
    10 minutes
    dasiglucagon 0.6 mg; 95% CI 8.0-12.0
    Median time to recovery
    35 minutes
    placebo; 95% CI 20.0 to -

    Source sentences

    Summary
    Median (95% CI) observed time to recovery was 10.0 (8.0; 12.0) minutes for dasiglucagon and 35.0 (20.0; -) minutes for placebo (P < .001).
    1 context sentence
    Summary · context
    In this double-blind trial, 45 participants with type 1 diabetes were randomized 3:1 to receive a single subcutaneous dose of dasiglucagon 0.6 mg or placebo following controlled induction of hypoglycaemia.
  2. 02HumanRandomized controlled trialEfficacy outcome

    Glucose recovery occurred within 15 minutes in 88% with dasiglucagon versus none with placebo (P < .01).

    In plain wordsMore participants recovered within 15 minutes with dasiglucagon than placebo.

    Peptide
    Dasiglucagon
    Outcome
    IncreaseRecovery within 15 minutes
    Study

    n = 45

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6 mg · subcutaneousAs given in this study (human).

    Measurements

    Recovery within 15 minutes
    88%
    dasiglucagon 0.6 mg

    Source sentences

    Summary
    Plasma glucose recovery was achieved within 15 minutes by 88% of participants receiving dasiglucagon versus none receiving placebo (P < .01).
    1 context sentence
    Summary · context
    In this double-blind trial, 45 participants with type 1 diabetes were randomized 3:1 to receive a single subcutaneous dose of dasiglucagon 0.6 mg or placebo following controlled induction of hypoglycaemia.
  3. 03HumanRandomized controlled trialEfficacy outcome

    Injection site (buttock or deltoid) was not shown to affect time to recovery (P = .84).

    In plain wordsRecovery time was not shown to differ between buttock and deltoid injections.

    Peptide
    Dasiglucagon
    Outcome
    No significant changeInjection site and recovery time
    Study

    n: not reported in source

    Comparator
    Buttock versus deltoid injection
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6 mg · subcutaneousAs given in this study (human).

    Measurements

    P value, injection site effect on time to recovery
    0.84
    buttock versus deltoid

    Source sentences

    Summary
    Site of injection (buttock or deltoid) was not shown to have any effect on time to recovery (P = .84).
    1 context sentence
    Summary · context
    In this double-blind trial, 45 participants with type 1 diabetes were randomized 3:1 to receive a single subcutaneous dose of dasiglucagon 0.6 mg or placebo following controlled induction of hypoglycaemia.
  4. 04HumanNon-randomized trialSafety outcome

    No serious adverse events occurred in the dasiglucagon trial.

    In plain wordsThe dasiglucagon trial reported no serious adverse events.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableSerious adverse events
    Study

    n = 45

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.6 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    No serious adverse events occurred.
    1 context sentence
    Summary · context
    In this double-blind trial, 45 participants with type 1 diabetes were randomized 3:1 to receive a single subcutaneous dose of dasiglucagon 0.6 mg or placebo following controlled induction of hypoglycaemia.
  5. 05HumanNon-randomized trialSafety outcome

    Nausea was common in dasiglucagon-treated participants with type 1 diabetes.

    In plain wordsNausea was common after dasiglucagon.

    Peptide
    Dasiglucagon
    Outcome
    Direction not reportedNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.6 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    As expected for glucagon treatment, nausea and vomiting were common adverse events in dasiglucagon-treated participants.
    1 context sentence
    Summary · context
    In this double-blind trial, 45 participants with type 1 diabetes were randomized 3:1 to receive a single subcutaneous dose of dasiglucagon 0.6 mg or placebo following controlled induction of hypoglycaemia.
  6. 06HumanNon-randomized trialSafety outcome

    Vomiting was common in dasiglucagon-treated participants with type 1 diabetes.

    In plain wordsVomiting was common after dasiglucagon.

    Peptide
    Dasiglucagon
    Outcome
    Direction not reportedVomiting
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.6 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    As expected for glucagon treatment, nausea and vomiting were common adverse events in dasiglucagon-treated participants.
    1 context sentence
    Summary · context
    In this double-blind trial, 45 participants with type 1 diabetes were randomized 3:1 to receive a single subcutaneous dose of dasiglucagon 0.6 mg or placebo following controlled induction of hypoglycaemia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.